Results 151 to 160 of about 949,070 (290)

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Anti-plasmodial activity of proteasome inhibitors against various <i>Plasmodium</i> species: a preclinical evaluation. [PDF]

Antimicrob Agents Chemother
Van Truong N, Nguyen T-K, Sy Thau N, Chu T-TH, Han J-H, Na S-H, Park W-S, Chun W-J, No JH, Lu F, Moon RW, Han E-T.   +11 more
europepmc   +1 more source

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

Two cases of proteasome inhibitors related thrombotic microangiopathies and literature review. [PDF]

Thromb J
An N, Shi P, Chen C.
europepmc   +1 more source

In Situ Bioorthogonal Synthesis of PROTACs via Dual‐Responsive Cleavage for Synergistic Photo‐Immunotherapy

Advanced Science, EarlyView.
A bioactive self‐delivering SNAP‐TAC platform responds to tumor‐associated cathepsin B and glutathione, enabling in situ bioorthogonal synthesis of a BRD4‐degrading proteolysis‐targeting chimera within the tumor microenvironment. The resulting BRD4 degradation and PD‐L1 downregulation synergize with photodynamic therapy‐induced immunogenic cell death ...
Shiqin Jian, Jiasha Wu, Fusheng Xu, Yan Zuo, Huaxing Shen, Rui Ji, Luyi Wang, Na Li, Yanting Sun, Yongsheng Yu, Yejiao Shi, Honggang Hu, Feng Xu, Dan Huang, Xiaochun Hu   +14 more
wiley   +1 more source

Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma. [PDF]

Ann Med Surg (Lond)
Aleem MR, Baloch K, Shahid M, Talha SS.
europepmc   +1 more source

Developing Metal–Polyphenol Network‐Based Single‐Protein Particle Encapsulation System for Sustained Release of Whey Protein to Mitigate Sarcopenia

Advanced Science, EarlyView.
Sarcopenia has emerged as a major health challenge in the aging population. Developing a sustained‐release system for whey protein may enhance its effectiveness in mitigating sarcopenia. Herein, a novel “single‐protein particle encapsulation” (SPPE) system is developed to protect whey protein and control its release.
Yafei Zhang, Yuning Zhang, Yongjian Ai, Yao Lu, Heng Quan, Zhen Zhang, Yuqi Wang, Yujia Luo, Xiaoxu Zhang, Yingying Lin, Sijia Song, Huiyuan Guo   +11 more
wiley   +1 more source

Thermodynamic Preference Between Deprotonation Pathways in Boronic Acid-Based Proteasome Inhibitors: Insights from a DFT Study. [PDF]

Pharmaceuticals (Basel)
Toshev N, Dimitrov I, Muradyan O, Delchev V, Dudev T.   +4 more
europepmc   +1 more source

Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1. [PDF]

Proc Natl Acad Sci U S A, 2023
Velez B, Razi A, Hubbard RD, Walsh R, Rawson S, Tian G, Finley D, Hanna J.   +7 more
europepmc   +1 more source

Lactylation‐Mediated HER2 Stabilization Promotes Trastuzumab Resistance in Gastric Cancer

Advanced Science, EarlyView.
Warburg effect‐derived lactate drives HER2 lactylation and trastuzumab resistance. Mechanistically, AARS1‐mediated lactylation stabilizes HER2 by inhibiting USP11‐dependent degradation and concurrently promotes HER2‐EGFR interaction. Importantly, inhibiting HER2 lactylation resensitizes gastric cancer cells to trastuzumab.
Meng Qian, Tongguan Tian, Zhenxiang Wang, Huihui Sun, Ming Zong, Ying Chen, Jie Xiong, Ye Chen, Zhiqian Hu, Tianming Li, Yanping Xu, Shuchang Xu   +11 more
wiley   +1 more source